Licensing · MENA · Announced 29 Jun 2026
Daewoong Pharmaceutical → Arcera Life Sciences
Licensing deal between Daewoong Pharmaceutical (South Korea) and Arcera Life Sciences (United Arab Emirates), covering Enavogliflozin, announced 29 Jun 2026. Value: $94m.
Parties: Daewoong Pharmaceutical (South Korea) → Arcera Life Sciences (United Arab Emirates)
- Deal type
- Licensing
- Value
- $94m
- Territory
- UAE, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain, Egypt, Iraq
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Enavogliflozin (SGLT2 inhibitor)
- Announced
- 29 Jun 2026
Our analysis
Why this matters.
Daewoong Pharmaceutical — South Korea's largest drugmaker by revenue — is taking its home-grown SGLT-2 inhibitor Envlo (enavogliflozin) into eight Middle East and North Africa markets: the six GCC states plus Egypt and Iraq.
The full analysis is free to read with a work email on this page.
Source: Arcera Life Sciences